Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04864119 · ClinicalTrials.gov registry record
DEFINing the PrEvalence and Characteristics of Coronary Artery Disease Among Patients With TYPE 2 Myocardial Infarction Using CT-FFR
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 50
- Enrollment target
NCT04864119: Completed study, sponsored by Massachusetts General Hospital.
NCT04864119 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04864119 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
Study Summary
The primary objectives of this study include: * determine the prevalence of coronary artery disease among patients with type 2 myocardial infarction * determine the prevalence of hemodynamically significant stenosis among patients with type 2 myocardial infarction The investigators hypothesize that patients with type 2 myocardial infarction will have a high burden of coronary artery plaque and a high prevalence of obstructive coronary artery disease with hemodynamic significance.
Primary Outcome
(defined as a stenosis of greater or equal to 70% in any epicardial vessel except left main coronary artery where greater or equal to 50% will be considered obstructive)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-04-11 |
| Est. Completion | 2024-03-11 |
What the finished NCT04864119 record still lists
NCT04864119 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04864119 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04864119 about?
NCT04864119 is a clinical study titled "DEFINing the PrEvalence and Characteristics of Coronary Artery Disease Among Patients With TYPE 2 Myocardial Infarction Using CT-FFR". The primary objectives of this study include: * determine the prevalence of coronary artery disease among patients with type 2 myocardial infarction * determine the prevalence of hemodynamically significant stenosis among patients with type 2 myocardial infarction The investigators hypothesize tha...
What is the current status of trial NCT04864119?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2021-04-11. Estimated completion is 2024-03-11.
Who is sponsoring clinical trial NCT04864119?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI